Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 2
1988 2
1989 1
1990 3
1991 4
1992 2
1993 11
1994 21
1995 33
1996 49
1997 43
1998 58
1999 74
2000 60
2001 88
2002 86
2003 99
2004 138
2005 138
2006 135
2007 131
2008 99
2009 138
2010 123
2011 110
2012 123
2013 124
2014 109
2015 137
2016 121
2017 125
2018 117
2019 150
2020 152
2021 143
2022 153
2023 127
2024 53

Text availability

Article attribute

Article type

Publication date

Search Results

2,964 results

Results by year

Filters applied: . Clear all
Page 1
Takayasu arteritis: an update.
Keser G, Aksu K, Direskeneli H. Keser G, et al. Turk J Med Sci. 2018 Aug 16;48(4):681-697. doi: 10.3906/sag-1804-136. Turk J Med Sci. 2018. PMID: 30114347 Free article. Review.
The rationale of medical treatment is to suppress both vascular and systemic inflammation with appropriate systemic immunosuppression, including corticosteroids and conventional immunosuppressive agents. In cases of refractory disease activity, leflunomide and biologic age …
The rationale of medical treatment is to suppress both vascular and systemic inflammation with appropriate systemic immunosuppression, inclu …
Therapeutic management in paediatric alopecia areata: A systematic review.
Waśkiel-Burnat A, Kołodziejak M, Sikora M, Stochmal A, Rakowska A, Olszewska M, Rudnicka L. Waśkiel-Burnat A, et al. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1299-1308. doi: 10.1111/jdv.17187. J Eur Acad Dermatol Venereol. 2021. PMID: 33630354 Review.
There were limited data considering children with alopecia areata treated with azathioprine, hydroxychloroquine, topical sildenafil, topical prostaglandin analogues, fractional carbon dioxide laser, leflunomide, mesalazine, apremilast, dupilumab, ustekinumab, efalizumab, b …
There were limited data considering children with alopecia areata treated with azathioprine, hydroxychloroquine, topical sildenafil, topical …
Leflunomide-Associated Pancytopenia.
Aldhafeeri A, Zerihun K, Khader Y, Altorok N. Aldhafeeri A, et al. Am J Ther. 2023 Nov-Dec 01;30(6):e563-e565. doi: 10.1097/MJT.0000000000001497. Epub 2022 Apr 11. Am J Ther. 2023. PMID: 35404332 No abstract available.
Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases.
Ibarra Barrueta O, García Martín E, López Sánchez P, Ramírez Herráiz E, Merino Bohórquez V, Ais Larisgoitia A. Ibarra Barrueta O, et al. Farm Hosp. 2023 Jan-Feb;47(1):39-49. doi: 10.1016/j.farma.2022.12.005. Epub 2023 Jan 27. Farm Hosp. 2023. PMID: 36710223 Free article. Review. English, Spanish.
Drugs contraindicated in pregnancy are topical retinoids, pimecrolimus, cyclooxygenase 2 inhibitors, methotrexate, mycophenolate mofetil, leflunomide, acitretin, and thiopurines. The lack of data advises against the use of apremilast, tofacitinib, baricitinib, anakinra, ab …
Drugs contraindicated in pregnancy are topical retinoids, pimecrolimus, cyclooxygenase 2 inhibitors, methotrexate, mycophenolate mofetil, …
Leflunomide: dermatologic perspective.
Sehgal VN, Verma P. Sehgal VN, et al. J Dermatolog Treat. 2013 Apr;24(2):89-95. doi: 10.3109/09546634.2011.595383. Epub 2011 Jul 31. J Dermatolog Treat. 2013. PMID: 21801113 Review.
Leflunomide, an isoxazole derivative, is a disease-modifying antirheumatic drug. ...Prime mode of action of leflunomide is through the inhibition of dihydroorotate dehydrogenase, a key enzyme in the de novo pyrimidine synthesis pathway used by lymphocytes for clonal …
Leflunomide, an isoxazole derivative, is a disease-modifying antirheumatic drug. ...Prime mode of action of leflunomide is thr …
Sustained Drug Treatment Alters the Gut Microbiota in Rheumatoid Arthritis.
Mei L, Yang Z, Zhang X, Liu Z, Wang M, Wu X, Chen X, Huang Q, Huang R. Mei L, et al. Front Immunol. 2021 Oct 14;12:704089. doi: 10.3389/fimmu.2021.704089. eCollection 2021. Front Immunol. 2021. PMID: 34721377 Free PMC article. Clinical Trial.
Here, we tracked the longitudinal changes in gut bacteria in 22 RA patients who were randomized into two groups and treated with Huayu-Qiangshen-Tongbi formula (HQT) plus methotrexate (MTX) or leflunomide (LEF) plus MTX. There were differences in the gut microbiome between …
Here, we tracked the longitudinal changes in gut bacteria in 22 RA patients who were randomized into two groups and treated with Huayu-Qiang …
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA; PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital Central Sur de Pemex. Alfaro-Lara R, et al. Reumatol Clin (Engl Ed). 2019 May-Jun;15(3):133-139. doi: 10.1016/j.reuma.2017.07.020. Epub 2017 Sep 1. Reumatol Clin (Engl Ed). 2019. PMID: 28867467 Free article. English, Spanish.
OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the first disease-modifying antirheumatic drug (DMARD). ...Leflunomide was linked to a greater increase in liver enzymes, but there were …
OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the …
Reply to DeVito.
Wang M, Hu K. Wang M, et al. Clin Infect Dis. 2021 Jun 15;72(12):e1165-e1166. doi: 10.1093/cid/ciaa1811. Clin Infect Dis. 2021. PMID: 33274380 No abstract available.
Leflunomide in dermatology.
Boyd AS. Boyd AS. J Am Acad Dermatol. 2012 Apr;66(4):673-9. doi: 10.1016/j.jaad.2011.08.025. Epub 2011 Oct 1. J Am Acad Dermatol. 2012. PMID: 21962758 Review.
Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necros …
Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This dr …
Concerning Trials Registration.
DeVito NJ. DeVito NJ. Clin Infect Dis. 2021 Jun 15;72(12):e1164-e1165. doi: 10.1093/cid/ciaa1808. Clin Infect Dis. 2021. PMID: 33270097 No abstract available.
2,964 results